New Product Planning

Challenge A European investor was refocusing its investment efforts and considering targeting the oncology cell therapy space. It had a particular interest in tumor infiltrating lymphocytes (TILs)...

Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the product in treating...

Challenge: Our client was a medical solutions provider specialising in AI applications applied to real-time analysis of medical imagery to provide clinicians with real-time decision-making...

Challenge: A research-focused biotech company developing a novel, first-in-class, next generation oral anticoagulant for the prevention of life-threatening thrombotic events asked Alacrita to...

Challenge: A Swiss biopharma company was developing a therapeutic for a severe orphan disorder. The company had successfully obtained Breakthrough Therapy Designation by the FDA and PRIME status by...

Challenge: A company with a microbiome-conditioning product was seeking the optimum strategic positioning to enable a trade sale to a major company. Unusually for a venture in this field, the company...

Challenge An established European pharma company needed an opportunity assessment for a reformulation of a marketed biologic.

Challenge: A clinical stage pharma company with development and commercialization rights to a novel treatment for GI indications wanted to gain marketing authorization in Europe. However, the...

Challenge: A clinical stage biopharma company developing a novel small molecule to treat a rare respiratory disorder had conducted an Advisory Board to finalize the design of later stage clinical...

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...

Challenge A privately held specialty pharmaceutical company focused in the field of psychiatry was conducting a Phase III clinical evaluation of its new formulation (one-per-day) of a commonly...

Challenge A Spanish university spinout with an integrated platform to discover and develop new antimicrobials and adjuvants with novel mechanisms of action, was advancing a potentiator program that...